ROUTE    CONTACT
zoeken
FOLLOW US:
Mission
Mission

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. Our mission is to identify patients at risk of developing heart attacks and strokes. The ultimate goal is to develop meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Bookmark and Share

Recently our company identified several novel biomarkers predictive for cardiovascular events. CAVΛDIS™ biomarkers form the basis for developing prognostic assays that enable individual cardiovascular risk assessment. Our proprietary biomarkers outperform traditional risk factors and show an impressive shifting power in patients classified as high or low risk according to classical risk factors. Improved risk stratification impacts clinical decision making as high-risk patient groups are likely to receive more aggressive treat-to-target medication schemes or may become eligible for novel biopharmaceuticals currently under development for cardiovascular indications.
Our goal is to develop clinically meaningful risk stratification tools that will help to personalize treatment and achieve better patient outcomes.

  • CAVΛDIS™ identified novel biomarkers predictive for cardiovascular events.
  • CAVΛDIS™ biomarkers form the basis for developing prognostic tests that allow individual risk assessment.
  • CAVΛDIS™ develops clinically meaningful risk stratification tools to personalize treatment and achieve better patient outcomes.
Related items
News
Get the latest insights in the business and research of CAVΛDIS™.

read more
Press Releases
Get up to date with the latest press releases from CAVΛDIS™.

read more